Halo Neuroscience, a San Francisco, CA-based developer of a neurotechnology platform for athletes, raised $9m in Series A funding.
The round was led by Lux Capital, with participation from Jazz Venture Partners, Andreessen Horowitz, SoftTech VC and Xfund.
The company will use the funds to launch its first product and expand operations.
Co-founded by Daniel Chao MD, MS, CEO, Brett Wingeier PhD, CTO, and Amol Sarva, Halo Neuroscience is finalizing and launching Halo Sport, its first product designed for athletes, which uses proprietary technology called Neuropriming to improve the brain’s response to training and drive accelerated performance gains.
Halo Sport is now available for elite teams and organizations with limited consumer release shippin in Fall 2016.